NEW YORK, Sept. 11, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of Sema4 Holdings Corp. shareholders. (NASDAQ: SMFR , SMFRW) and Medtronic PLC (NYSE: MDT). Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Sema4 Holdings Corp. (NASDAQ: SMFR, SMFRW)

Class Period: March 14, 2022 – August 15, 2022

Lead Plaintiff Deadline: November 7, 2022

On August 15, 2022, after the market closed, Sema4 announced changes to its R&D leadership team, including the resignation of defendant Schadt from his roles as President and Chief R&D Officer. The company also announced that it will be shedding approximately 13% of its workforce as part of a series of corporate reorganizations and realignments. During the related conference call, Sema4 announced that this quarter, related to negotiations with “one of [Sema4’s] major commercial payers regarding potential reimbursement of payments for Sema4 carrier screening services provided from 2018 through early 2022.”

As a result of this news, Sema4’s stock fell $0.80, or 33.3%, on unusually high trading volume to close at $1.60 per share on August 16, 2022.

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors: (1) that there was a significant risk that Sema4 would reverse a substantial amount of previously recognized revenue that it was unable to recover from third-party payers; (2) that the company experienced …